UBS Group AG Sells 842,412 Shares of Heron Therapeutics, Inc. $HRTX

UBS Group AG cut its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 28.7% during the fourth quarter, Holdings Channel reports. The fund owned 2,091,669 shares of the biotechnology company’s stock after selling 842,412 shares during the quarter. UBS Group AG’s holdings in Heron Therapeutics were worth $2,719,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Concurrent Investment Advisors LLC acquired a new position in shares of Heron Therapeutics during the 4th quarter worth approximately $42,000. Palumbo Wealth Management LLC increased its holdings in shares of Heron Therapeutics by 19.8% during the 4th quarter. Palumbo Wealth Management LLC now owns 259,413 shares of the biotechnology company’s stock worth $337,000 after acquiring an additional 42,907 shares during the last quarter. Congress Park Capital LLC increased its holdings in shares of Heron Therapeutics by 6.1% during the 4th quarter. Congress Park Capital LLC now owns 3,067,475 shares of the biotechnology company’s stock worth $3,988,000 after acquiring an additional 177,318 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Heron Therapeutics by 39.1% during the 4th quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 6,858 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Heron Therapeutics by 35.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,292,444 shares of the biotechnology company’s stock worth $1,628,000 after acquiring an additional 339,364 shares during the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Stock Up 2.9%

HRTX opened at $0.88 on Wednesday. Heron Therapeutics, Inc. has a fifty-two week low of $0.74 and a fifty-two week high of $2.30. The company has a debt-to-equity ratio of 17.51, a quick ratio of 1.51 and a current ratio of 2.53. The company has a market capitalization of $167.19 million, a P/E ratio of -4.91 and a beta of 1.70. The stock has a fifty day moving average of $0.93 and a 200-day moving average of $1.13.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The firm had revenue of $34.71 million for the quarter, compared to analyst estimates of $36.72 million. On average, equities analysts expect that Heron Therapeutics, Inc. will post -0.05 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Zacks Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. HC Wainwright reissued a “buy” rating on shares of Heron Therapeutics in a report on Monday, May 11th. Wall Street Zen lowered Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $4.50.

Heron Therapeutics Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.